+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Protein Therapeutics - Global Strategic Business Report 2026

  • PDF Icon

    Report

  • 163 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5309803
The global market for Protein Therapeutics was valued at US$351.3 Billion in 2025 and is projected to reach US$650 Billion by 2032, growing at a CAGR of 9.2% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Protein Therapeutics Market - Key Trends and Drivers Summarized

Revolutionizing Medicine: The Expanding Market for Protein Therapeutics

Protein therapeutics have emerged as a cornerstone of modern medicine, offering targeted and effective treatments for a wide range of diseases, including cancer, autoimmune disorders, and genetic conditions. Unlike traditional small-molecule drugs, protein therapeutics such as monoclonal antibodies, cytokines, and recombinant proteins are designed to interact with specific biological targets, resulting in highly precise therapeutic effects. These biologics are engineered to mimic or modulate natural proteins within the body, providing treatment options that are often more effective and have fewer side effects than conventional therapies. The increasing understanding of molecular biology and genetics has further fueled the development of protein therapeutics, making them indispensable in the treatment of complex and chronic diseases.

How Are Technological Innovations Shaping the Protein Therapeutics Market?

Technological innovations have significantly advanced the field of protein therapeutics, enhancing the efficiency, specificity, and scalability of these treatments. The advent of recombinant DNA technology and monoclonal antibody production has revolutionized the development of protein-based drugs, enabling the mass production of biologics with high purity and consistency. Innovations in protein engineering, such as the development of bispecific antibodies and antibody-drug conjugates, have further expanded the therapeutic potential of proteins by combining multiple mechanisms of action into a single treatment. Additionally, advancements in drug delivery systems, such as nanoparticles and sustained-release formulations, have improved the stability and bioavailability of protein therapeutics, making them more effective and convenient for patients. These technological advancements are driving the adoption of protein therapeutics in clinical practice.

What Are the Emerging Applications of Protein Therapeutics?

Emerging applications of protein therapeutics are expanding their role in medicine beyond traditional indications. In oncology, protein therapeutics are being used to develop novel immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, that harness the body’s immune system to fight cancer. The rise of personalized medicine has also driven the use of protein therapeutics in the development of targeted therapies, tailored to the genetic and molecular profiles of individual patients. In the field of regenerative medicine, growth factors and other protein-based treatments are being explored to promote tissue repair and regeneration in conditions such as heart disease and neurodegenerative disorders. These emerging applications are broadening the scope of protein therapeutics, making them a critical component of future medical treatments.

What Are the Key Growth Drivers in the Market?

The growth in the protein therapeutics market is driven by several factors. The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is a major driver, as these conditions often require targeted and effective treatments that protein therapeutics can provide. Technological advancements in protein engineering, recombinant DNA technology, and drug delivery systems have significantly improved the development and administration of protein-based drugs, driving their adoption in clinical settings. The rise of personalized medicine has also spurred the demand for protein therapeutics, as these treatments can be tailored to the specific needs of individual patients. Additionally, the growing focus on biologics in pharmaceutical research and the expansion of applications in areas such as oncology and regenerative medicine are further propelling the market. As the global healthcare landscape continues to evolve, the demand for protein therapeutics is expected to grow significantly.

Report Scope

The report analyzes the Protein Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Product (mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product, Other Products); Application (Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application, Other Applications).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the mAbs Product segment, which is expected to reach US$191.7 Billion by 2032 with a CAGR of a 7.3%. The Human Insulin Product segment is also set to grow at 9.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $102.8 Billion in 2025, and China, forecasted to grow at an impressive 8.9% CAGR to reach $115 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Protein Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Protein Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Protein Therapeutics Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, Amgen, Inc., AstraZeneca PLC, Baxter International, Inc., Biogen, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Protein Therapeutics market report include:

  • Abbott Laboratories
  • Amgen, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Chugai Pharmaceutical Co., Ltd.
  • Diasome Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Generex Biotechnology Corporation
  • GeneScience Pharmaceuticals Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck Serono SA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Protein Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Diseases Propels Market Growth
  • Increasing Use in Targeted and Personalized Medicine Expands Addressable Market Opportunity
  • Technological Advancements in Protein Engineering Strengthen Market Position
  • Growing Focus on Biopharmaceuticals Drives Adoption of Protein Therapeutics
  • Surge in Demand for Monoclonal Antibodies Generates New Opportunities
  • Development of Biosimilars and Biobetters Sustains Market Growth
  • Expanding Applications in Oncology and Autoimmune Diseases Throws Spotlight on Market Potential
  • Surge in Demand for Protein Therapeutics in Rare Diseases Expands Market Horizons
  • Growing Awareness of the Benefits of Protein-Based Drugs Drives Market Adoption
  • Innovations in Drug Delivery Systems Generate New Market Opportunities
  • Rising Demand for Cost-Effective and Scalable Therapeutics Throws Spotlight on Market Dynamics
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 2: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 3: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 4: World Protein Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 5: World Recent Past, Current & Future Analysis for Protein Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Protein Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Protein Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for mAbs Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for mAbs Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for mAbs Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Human Insulin Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Human Insulin Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Human Insulin Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Erythropoietin Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Erythropoietin Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Erythropoietin Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Clotting Factors Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Clotting Factors Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Clotting Factors Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Metabolic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Metabolic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Metabolic Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Immunologic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Immunologic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Immunologic Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Hematological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 35: USA Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 36: USA Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: USA 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 38: USA Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 39: USA Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 40: USA 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
CANADA
  • Table 41: Canada Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 42: Canada Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 43: Canada 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 44: Canada Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 45: Canada Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 46: Canada 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
JAPAN
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 47: Japan Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 48: Japan Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 49: Japan 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 50: Japan Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 51: Japan Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 52: Japan 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
CHINA
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 53: China Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 54: China Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 55: China 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 56: China Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 57: China Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 58: China 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
EUROPE
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 59: Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 60: Europe Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 61: Europe 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 62: Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 63: Europe Historic Review for Protein Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 64: Europe 13-Year Perspective for Protein Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 65: Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 66: Europe Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 67: Europe 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
FRANCE
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 68: France Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 69: France Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 70: France 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 71: France Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 72: France Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 73: France 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
GERMANY
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 74: Germany Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 75: Germany Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 76: Germany 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 77: Germany Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 78: Germany Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 79: Germany 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
ITALY
  • Table 80: Italy Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 81: Italy Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 82: Italy 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 83: Italy Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 84: Italy Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 85: Italy 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 86: UK Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 87: UK Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 88: UK 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 89: UK Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 90: UK Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 91: UK 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of Europe Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of Europe 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 96: Rest of Europe Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 97: Rest of Europe 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Protein Therapeutics by Application - Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 100: Asia-Pacific 13-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders Application, Immunologic Disorders Application, Hematological Disorders Application, Cancer Application and Other Applications for the Years 2020, 2026 & 2032
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Protein Therapeutics by Product - mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 103: Asia-Pacific 13-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for mAbs Product, Human Insulin Product, Erythropoietin Product, Clotting Factors Product and Other Products for the Years 2020, 2026 & 2032
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Amgen, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Chugai Pharmaceutical Co., Ltd.
  • Diasome Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Generex Biotechnology Corporation
  • GeneScience Pharmaceuticals Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck Serono SA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.

Table Information